Xontogeny

After a bruising turn as Sarepta CEO, Chris Garabedian is back in biotech with a new role as godfather to a bunch of startups
Endpoints
Thu, 05/18/17 - 09:46 am
Sarepta Therapeutics
Chris Garabedian
Xontogeny
startups